Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. Their aim is to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.
To learn more about Resverlogix Corp. please visit: https://www.resverlogix.com
Resverlogix Corp trades on the Toronto Stock Exchange under the symbol RV